BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31590696)

  • 1. CyclinD1 inhibits dicer and crucial miRNA expression by chromatin modification to promote the progression of intrahepatic cholangiocarcinoma.
    Qi Y; Wang D; Huang W; Wang B; Huang D; Xiong F; Chen X; Chen Y
    J Exp Clin Cancer Res; 2019 Oct; 38(1):413. PubMed ID: 31590696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
    Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
    J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CircRTN4IP1 regulates the malignant progression of intrahepatic cholangiocarcinoma by sponging miR-541-5p to induce HIF1A production.
    Tang J; Wang R; Tang R; Gu P; Han J; Huang W
    Pathol Res Pract; 2022 Feb; 230():153732. PubMed ID: 34974242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dicer promotes tumorigenesis by translocating to nucleus to promote SFRP1 promoter methylation in cholangiocarcinoma cells.
    Cheng W; Qi Y; Tian L; Wang B; Huang W; Chen Y
    Cell Death Dis; 2017 Feb; 8(2):e2628. PubMed ID: 28230864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA MT1JP plays a protective role in intrahepatic cholangiocarcinoma by regulating miR-18a-5p/FBP1 axis.
    Zhao W; Zhao J; Guo X; Feng Y; Zhang B; Tian L
    BMC Cancer; 2021 Feb; 21(1):142. PubMed ID: 33557774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
    Li H; Zhou ZQ; Yang ZR; Tong DN; Guan J; Shi BJ; Nie J; Ding XT; Li B; Zhou GW; Zhang ZY
    Hepatology; 2017 Jul; 66(1):136-151. PubMed ID: 28194813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA-CCAT1 Promotes Migration, Invasion, and EMT in Intrahepatic Cholangiocarcinoma Through Suppressing miR-152.
    Zhang S; Xiao J; Chai Y; Du YY; Liu Z; Huang K; Zhou X; Zhou W
    Dig Dis Sci; 2017 Nov; 62(11):3050-3058. PubMed ID: 28921383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.
    Li J; Tian F; Li D; Chen J; Jiang P; Zheng S; Li X; Wang S
    FEBS Lett; 2014 Sep; 588(18):3491-500. PubMed ID: 25131931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression.
    Huang CK; Aihara A; Iwagami Y; Yu T; Carlson R; Koga H; Kim M; Zou J; Casulli S; Wands JR
    Cancer Lett; 2016 Sep; 380(1):153-62. PubMed ID: 27364974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma.
    Zhang MX; Gan W; Jing CY; Zheng SS; Yi Y; Zhang J; Xu X; Lin JJ; Zhang BH; Qiu SJ
    Mol Carcinog; 2019 Jan; 58(1):19-30. PubMed ID: 30182496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma.
    Chen YJ; Luo J; Yang GY; Yang K; Wen SQ; Zou SQ
    World J Gastroenterol; 2012 Aug; 18(29):3849-61. PubMed ID: 22876037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
    Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
    Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma.
    Chen Y; Gao W; Luo J; Tian R; Sun H; Zou S
    Oncol Rep; 2011 Feb; 25(2):443-51. PubMed ID: 21165562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122.
    Zhu H; Mi Y; Jiang X; Zhou X; Li R; Wei Z; Jiang H; Lu J; Sun X
    J Cancer Res Clin Oncol; 2016 May; 142(5):969-80. PubMed ID: 26825606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.
    Wang LJ; He CC; Sui X; Cai MJ; Zhou CY; Ma JL; Wu L; Wang H; Han SX; Zhu Q
    Oncotarget; 2015 Mar; 6(8):5932-46. PubMed ID: 25803229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma.
    Liu Z; Jin ZY; Liu CH; Xie F; Lin XS; Huang Q
    Int J Clin Exp Pathol; 2015; 8(5):4684-94. PubMed ID: 26191158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.
    Chen J; Li Z; Chen J; Du Y; Song W; Xuan Z; Zhao L; Song G; Song P; Zheng S
    Clin Transl Oncol; 2020 Mar; 22(3):392-400. PubMed ID: 31264147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
    Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
    Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. circHMGCS1-016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma.
    Xu YP; Dong ZN; Wang SW; Zheng YM; Zhang C; Zhou YQ; Zhao YJ; Zhao Y; Wang F; Peng R; Tang MC; Bai DS; Huang XY; Guo CY
    J Exp Clin Cancer Res; 2021 Sep; 40(1):290. PubMed ID: 34526098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.